Search PubMed⌕ Search

Biomedical subjects

M Yasue

Publications and source records attributed to M Yasue.

At least 109 records · Page 6Linked to original sources
PubMed1983

[Adjuvant immunochemotherapy combined with OK-432 following surgery of stomach cancer].

Postoperative immunochemotherapy with mitomycin C (MMC), 5-fluorouracil (5-FU) and OK-432 was evaluated as adjuvant therapy for curative resection in the cases of gastric cancer. One hundred and twenty-two patients (28 were excluded) were randomly assigned to 3 groups: Group A-MMC and 5-FU (28 cases); Group B-MMC, 5-FU and OK-432 (33 cases); Group C-control (33 cases). There were no differences in the back ground factors influencing survival time among each group. Group B showed better results in survival rate and disease free interval as compared with Group A or C. Minor and reversible side effects such as enterogastric disorder, leukopenia (less than 3000/mm3), thrombo cytopenia (less than 7 X 10(4)/mm3) and elevation of serum transaminase (S-GPT greater than or equal to 100 unit) were equivalently observed in frequency in each Group A and B, but they were milder in Group B than Group A.

Aged↗
PubMed1981

A controlled study of maintenance chemoimmunotherapy vs immunotherapy alone immediately following palliative gastrectomy and induction chemoimmunotherapy for advanced gastric cancer. Tokai cooperative study group for adjuvant chemoimmunotherapy of stomach cancer.

A randomized trial of surgical adjuvant chemoimmunotherapy was conducted in patients who had undergone palliative gastrectomy for previously untreated advanced stomach cancer. First, all patients received the same induction chemoimmunotherapy with MFC (mitomycin C, 5-fluorouracil, and cytosine arabinoside) plus OK-432 for 6 weeks after surgery. The patients were then randomized to receive either chemoimmunotherapy with MFC plus OK-432 (group A) or immunotherapy with OK-432 alone (group B) for maintenance. The survival rate of patients was significantly higher in group B (44 cases) than in group A (39 cases) during the first 9 months after the start of induction therapy (P less than 0.05). A further division of patients in terms of carcinoma histology revealed a difference in survival rate only in patients with an undifferentiated histology (poorly differentiated adenocarcinoma and signet-ring cell carcinoma), and not in those with a differentiated histology (papillary, tubular, and mucinous adenocarcinomas). These results indicate that simple immunotherapy with Ok-432 is better for maintenance than chemoimmunotherapy involving MFC, particularly in patients with undifferentiated gastric carcinomas.

Antineoplastic Agents↗
PubMed1977

Asymptomatic transient hyperamylasemia after a large intravenous dose of steroid hormone.

Asymptomatic transient hyperamylasemia accompanied with hyperamylasuria immediately after an intravenous dose of 1 gm methylprednisolone has been observed in renal homotransplantation patients. Similar phenomena have also been seen in the other operative patients who received certain amounts of steroid hormone intravenously during their procedure. These cases of hyperamylasemia and hyperamylasuria were studied in detail including time-sequence observation, amylase-creatinine clearance ratio, and amylase isoenzyme analysis. The hyperamylasemia is not due to the general anesthesia or the surgical procedure. It is apparently not due to simple retention of enzyme from poor kidney function. The source of hyperamylasemia is the pancreas mediated by large intravenous doses of steroid hormone.

Aged↗